title: Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.
abstract: BACKGROUND
  Current literature suggests that the incidence of sexual dysfunction secondary to fluvoxamine therapy is 1% to 8%, while other selective serotonin reuptake inhibitors may have rates as high as 75%. The objective of this study was to determine the incidence of sexual dysfunction secondary to fluvoxamine in healthy volunteers.
  
  
  METHODS
  20 healthy volunteers (10 men, 10 premenopausal women) had adverse effects assessed at 6 visits while not receiving fluvoxamine, then twice while taking 150 mg fluvoxamine daily. Assessments occurred at 2-week intervals. Incidence rates for sexual dysfunction were calculated.
  
  
  RESULTS
  No sexual dysfunction was reported prior to fluvoxamine therapy. After 2 weeks and 4 weeks of therapy respectively, sexual dysfunction occurred in 20% (N = 4) and 35% (N = 7) of the healthy volunteers.
  
  
  CONCLUSIONS
  The incidence of sexual dysfunction during fluvoxamine therapy in healthy volunteers is 35%. This incidence is higher than previously reported and similar to that of other selective serotonin reuptake inhibitors.
authors: Clinical Pharmacology Research Center and Department of Medicine, Bassett Healthcare, Cooperstown, NY 13326-1394, USA. nafziger@iex.net
authors: A N
authors: AN
authors: Nafziger
authors: J S
authors: JS
authors: Bertino
authors: A I
authors: AI
authors: Goss-Bley
authors: A D
authors: AD
authors: Kashuba
mesh_terms: D000328:Adult; D001835:Body Weight; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D008297:Male; D017697:Premenopause; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012737:Sex Factors; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D011795:Surveys and Questionnaires
chemical_list: D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors